MRK · Company research
1 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Merck & expects to report results from its Phase 3 study of sacituzumab tirumotecan (MK-2870) for Advanced/recurrent endometrial cancer (TroFuse-005) in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Merck & presented data on Oncology portfolio (KEYTRUDA, sac-TMT, I-DXd, etc.) for Oncology at a medical meeting on Oct 26, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA’s decision on Merck &’s Ifinatamab deruxtecan (I-DXd, DS-7300; Daiichi Sankyo/Merck) for Extensive-stage small cell lung cancer after platinum-based chemotherapy was due on Oct 10, 2026. The outcome isn’t recorded here yet — the linked source has the latest.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA’s decision on Merck &’s WELIREG (belzutifan) + LENVIMA (lenvatinib) for Advanced clear cell RCC after PD-1/PD-L1 therapy (LITESPARK-011) was due on Oct 4, 2026. The outcome isn’t recorded here yet — the linked source has the latest.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA’s decision on Merck &’s WINREVAIR (sotatercept-csrk) for Pulmonary arterial hypertension (recently diagnosed patients; label update) was due on Sep 21, 2026. The outcome isn’t recorded here yet — the linked source has the latest.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Remigromig (MK-3000) Ph3 BRUNELLO DME primary completion, in Sep 2026. A company milestone for Merck & (remigromig (MK-3000) for Diabetic macular edema): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Merck & reported results from its Phase 3 study of intismeran autogene (V940/mRNA-4157) + KEYTRUDA for Adjuvant resected stage IIB-IV melanoma on Aug 19, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Tulisokibart Ph3 ATLAS UC trial primary completion, in Aug 2026. A company milestone for Merck & (tulisokibart (MK-7240) for Moderately-to-severely active ulcerative colitis): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Merck &’s LIPFENDRA (enlicitide) for Hypercholesterolemia including HeFH on Jul 16, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Merck & reported results from its Phase 3 study of tulisokibart (MK-7240) for Moderately to severely active ulcerative colitis on Jun 22, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Merck &’s KEYTRUDA (pembrolizumab) + WELIREG (belzutifan) for Adjuvant clear cell renal cell carcinoma on Jun 12, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Merck & reported results from its Phase 3 study of Trodelvy (sacituzumab govitecan) + KEYTRUDA for First-line PD-L1 TPS >=50% metastatic NSCLC on Jun 8, 2026. The study missed its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Merck & reported results from its Phase 3 study of sacituzumab tirumotecan (sac-TMT, MK-2870) for Advanced or recurrent endometrial cancer on May 18, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Merck & reported results from its Phase 3 study of KEYTRUDA + LENVIMA + WELIREG; MK-1308A + LENVIMA for First-line advanced clear cell renal cell carcinoma on Apr 21, 2026. The study missed its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to MRK.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.